One third of the drugs approved by the FDA and the EMA have a high therapeutic value
In a retrospective analysis recently published in the British Medical Journal, it was observed that a third of the drugs […]
See more ▸
ROM: the new Oncology Network implemented in Madrid
Madrid has implemented a new model for the medical management of cancer patients aiming to improve cancer care. The goal […]
See more ▸
FDA accept ‘Priority Review’ for lurbinectedin in small-cell lung cancer
PharmaMar and Jazz Pharmaceuticals have just announced that the American regulatory agency FDA has accepted the Priority Review of lurbinectedin […]
See more ▸
Approved a new Royal Decree that reinforces control over homeopathic drugs.
The new amendment to Royal Decree 1345/2007 includes, among other changes, the obligation to conduct clinical trials with homeopathic drugs with therapeutic indications.
See more ▸
AEMPS issues an update of instructions for conducting clinical trials
New instructions define more precisely the process for the notification of serious and unexpected adverse reactions in clinical trials.
See more ▸
Half of clinical trials conducted in the EU do not report the results obtained
Of the 7,274 clinical trials that should have included their results in the EUCTR, only 3,601 (50%) had done so at the time of the analysis.
See more ▸
The European registry of clinical trials is expected to be accessible by 2020
The European Medicines Agency will launch a European registry of clinical trials in 2020, which will complement existing registries.
See more ▸
Novartis promotes training in genitourinary cancer with SOGUG
The Advanced Program in Genitourinary Clinical Research (PAIC-GU) aims to improve the training of healthcare professionals specialized in genitourinary cancers.
See more ▸